AbbVie Beat Expectations

AbbVie (ABBV) reported earnings of $2.46 per share on revenue of $13.34 billion for the first quarter ended March 2025. The consensus earnings estimate was $2.39 per share on revenue of $12.88 billion. The Earnings Whisper number was $2.41 per share. The company beat expectations by 2.07% while revenue grew 8.39% on a year-over-year basis.

The company said it expects 2025 earnings of $12.22 to $12.42 per share, excluding items of $0.13 per share. The company's previous guidance was earnings of $12.12 to $12.32 per share, and the current consensus earnings estimate is $12.19 per share for the year ending December 31, 2025.

AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn' disease, HIV, cystic fibrosis complications.